-
公开(公告)号：US12024570B2
公开(公告)日：2024-07-02
申请号：US17070129
申请日：2020-10-14
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Aynur Hermann , Ella Ioffe , Elena Burova , Gavin Thurston , William Olson
CPC classification number: C07K16/40 , A61K39/395 , A61P35/00 , C07K16/2818 , C12N15/62 , A61K2039/507 , A61K2039/545 , A61K2300/00 , C07K16/2809 , C07K16/2863 , C07K16/2887 , C07K2317/21 , C07K2317/33 , C07K2317/76 , C07K2317/92
Abstract: The present invention provides antibodies that bind to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that specifically bind to CTLA-4. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing CTLA-4 activity, thus providing a means of activating T-cells and/or for treating a disease or disorder such as cancer or viral infection.
-
公开(公告)号：US20240209102A1
公开(公告)日：2024-06-27
申请号：US18523048
申请日：2023-11-29
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Jamie M. Orengo , Jeanne Allinne , Andrew J. Murphy , George D. Yancopoulos
IPC: C07K16/28 , A61K38/17 , A61K39/00 , A61K39/395 , A61K45/06 , A61P1/00 , A61P1/04 , A61P9/14 , A61P11/00 , A61P11/02 , A61P11/06 , A61P17/00 , A61P17/06 , A61P25/00 , A61P29/00 , A61P37/00 , A61P37/08 , C07K14/715 , C07K16/24
CPC classification number: C07K16/2866 , A61K38/1793 , A61K39/3955 , A61K45/06 , A61P1/00 , A61P1/04 , A61P9/14 , A61P11/00 , A61P11/02 , A61P11/06 , A61P17/00 , A61P17/06 , A61P25/00 , A61P29/00 , A61P37/00 , A61P37/08 , C07K14/7155 , C07K16/244 , A61K2039/507 , C07K2317/21 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2319/00
Abstract: The present invention provides methods for treating inflammatory diseases, or conditions associated with, or resulting in part from, elevated levels of IL-33 and IL-4, in particular inflammatory lung disorders. The methods of the present invention comprise administering to a subject in need thereof one or more therapeutically effective doses of an IL-33 antagonist alone or in combination with one or more therapeutically effective doses of an IL-4R antagonist. In certain embodiments, the methods of the present invention include use of the antagonists to treat any inflammatory disease or condition mediated in part by enhanced IL-33-mediated signaling and IL-4-mediated signaling.
-
公开(公告)号：US20240209074A1
公开(公告)日：2024-06-27
申请号：US18545795
申请日：2023-12-19
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Amanda Atanasio , Gary Herman , Meagan P. O'Brien , Jamie M. Orengo , Lorah Perlee
IPC: C07K16/18 , A61K39/00 , A61K39/395 , A61P37/08
CPC classification number: C07K16/18 , A61K39/395 , A61P37/08 , A61K2039/505 , A61K2039/545 , C07K2317/565
Abstract: The present disclosure provides methods for treating, preventing, or ameliorating one or more symptoms of birch allergy or allergic disease in a subject by administering to the subject an antibody or antigen-binding fragment thereof that binds Bet v 1, or a cocktail of antibodies or antigen-binding fragments thereof that bind Bet v 1.
-
公开(公告)号：US20240199751A1
公开(公告)日：2024-06-20
申请号：US18495182
申请日：2023-10-26
Applicant: SANOFI BIOTECHNOLOGY , REGENERON PHARMACEUTICALS, INC.
Inventor： Marius Ardeleanu , Namita A. Gandhi , Neil Graham , Stephane C. Kirkesseli , Sudeep Kundu , Ross E. Rocklin , Allen Radin , Steven P. Weinstein , Jennifer Davidson Hamilton , Jeffrey Ming
IPC: C07K16/28 , A61K39/00 , A61K39/395 , A61K45/06 , C07K16/24 , C12Q1/6883 , G01N33/68
CPC classification number: C07K16/2866 , A61K39/39541 , A61K39/3955 , A61K45/06 , C07K16/247 , C12Q1/6883 , G01N33/6854 , G01N33/6863 , G01N33/6893 , A61K2039/505 , A61K2039/54 , C07K2317/21 , C07K2317/565 , C07K2317/76 , C12Q2600/106 , C12Q2600/158 , G01N2333/521 , G01N2800/122 , G01N2800/52
Abstract: The present invention provides methods for treating or preventing asthma and associated conditions in a patient. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody.
-
公开(公告)号：US20240189319A1
公开(公告)日：2024-06-13
申请号：US18552303
申请日：2022-03-25
Applicant: Regeneron Pharmaceuticals, Inc
Inventor： Thomas NITTOLI , Anna ZUMSTEG
IPC: A61K31/538 , A61K38/14 , A61P31/04
CPC classification number: A61K31/538 , A61K38/14 , A61P31/04
Abstract: The disclosure relates to rifamycin analog compounds in combination with vancomycin, and pharmaceutical compositions and dosage forms comprising same, capable of inhibiting bacterial growth (e.g., S. aureus growth) and treating bacterial infections (e.g., S. aureus infections). The disclosure further relates to methods of use thereof to inhibit bacterial growth, treat bacterial infections. and treat disease with rifamycin analog compounds in combination with vancomycin. The disclosure further relates to methods of enhancing efficacy of rifamycin analog compounds and/or vancomycin.
-
Patent Agency Ranking
公开(公告)号：US20240182887A1
公开(公告)日：2024-06-06
申请号：US18503447
申请日：2023-11-07
Applicant: Regeneron Pharmaceuticals, Inc.
CPC classification number: C12N15/1079 , C12Q1/6874 , G01N33/5008 , G16B20/00 , G16B25/00 , G16B30/00
Abstract: Methods and systems for CRISPR positive selection are described. CRISPR positive selection uses DNA sequencing to identify genes that their perturbation by CRISPR guide RNAs is correlated to the phenotype. In some aspects, disclosed are genome-wide CRISPR/Cas9 screening methods to identify genetic modifiers. Also disclosed are the apparatuses used for performing the methods.
-
公开(公告)号：US20240180130A1
公开(公告)日：2024-06-06
申请号：US18391184
申请日：2023-12-20
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： John McWhirter , Cagan Gurer , Karolina A. Meagher , Lynn Macdonald , Andrew J. Murphy
IPC: A01K67/0278 , C07K16/00 , C12N15/10
CPC classification number: A01K67/0278 , C07K16/00 , C12N15/1003 , A01K2217/052 , A01K2217/072 , A01K2227/105 , A01K2267/01 , C07K2317/10 , C07K2317/14 , C07K2317/24 , C07K2317/51 , C07K2317/56 , C07K2317/64
Abstract: Non-human animals, e.g., mammals, e.g., mice or rats, are provided comprising an immunoglobulin heavy chain locus that comprises a rearranged human immunoglobulin heavy chain variable region nucleotide sequence. The rearranged human immunoglobulin heavy chain variable region nucleotide sequence may be operably linked to a heavy or light chain constant region nucleic acid sequence. Also described are genetically modified non-human animals comprising an immunoglobulin light chain locus comprising one or more but less than the wild type number of human immunoglobulin light chain variable region gene segments, which may be operably linked to a light chain constant region nucleic acid sequence. Also provided are methods for obtaining nucleic acid sequences that encode immunoglobulin light chain variable domains capable of binding an antigen in the absence of a heavy chain.
-
公开(公告)号：US12000840B2
公开(公告)日：2024-06-04
申请号：US17327889
申请日：2021-05-24
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Yuan Mao
CPC classification number: G01N33/6851 , C07K16/065 , G16B20/00 , G16B40/10 , H01J49/305
Abstract: A method for determining an amino acid sequence of a polypeptide, including comprising: contacting a first sample containing the polypeptide with a first protease (e.g., Trypsin) to produce a first set of digested peptide fragments; fragmenting the first set of digested peptide fragments to produce a first set of fragmented peptide ions; determining masses of the first set of fragmented peptide ions; contacting a second sample containing the polypeptide with a second protease (e.g., Tryp-N); fragmenting the second set of digested peptide fragments to produce a second set of fragmented peptide ions; selecting pairs of peptide ions from the first and the second set of fragmented peptide ions that differ in mass by a mass of an arginine amino acid residue or a lysine amino acid residue; assigning an ion type (either N-terminal peptide ion or C-terminal peptide ion) to the selected pairs of the peptide ions from two sets of fragmented peptide ions; selecting a mass ladder of the same-type peptide ions in either set of fragmented peptide ions with incremental mass by the mass of amino acid residue(s), and assembling the identified amino acid residues from the mass ladder to determine the amino acid sequence of the polypeptide of interest.
-
公开(公告)号：US12000839B2
公开(公告)日：2024-06-04
申请号：US18154401
申请日：2023-01-13
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Shunhai Wang
CPC classification number: G01N33/6848 , A61K39/395 , G01N1/28 , G01N30/7233 , G01N33/6854 , G01N2030/027 , G01N2030/8831 , G01N2458/15
Abstract: Compositions and methods for analyzing disulfide bonds are provided. An exemplary method includes preparing peptide standards having no disulfide bonds, scrambled disulfide bond peptide standards, and native disulfide bond peptide standards according to the sequence of the region of the protein drug product that includes the disulfide bond, digesting a sample of protein drug product into peptides, separating the protein drug product peptides, analyzing the protein drug product peptides and the peptide standards, identifying scrambled and native disulfide bond peptides by retention time, and quantifying the level of scrambled disulfide bond peptides.
-
公开(公告)号：US12000811B2
公开(公告)日：2024-06-04
申请号：US17951614
申请日：2022-09-23
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Yuetian Yan , Shunhai Wang
IPC: G01N30/72 , G01N33/563 , G01N33/68
CPC classification number: G01N30/7266 , G01N33/563 , G01N33/6857
Abstract: Methods and system for identifying and quantifying antibody fragments and identifying the site of fragmentation on an antibody are provided herein.
-
-
-
-
-
-
-
-
-
Search Results
2865
records
(took 0.036 seconds)
